Treatment News : HIV Meds Much Cheaper Globally, Unless They're Newer Drugs

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 8, 2013

HIV Meds Much Cheaper Globally, Unless They're Newer Drugs

Thanks to increased competition among generic manufacturers, the price of first- and second-line antiretroviral (ARV) therapies to treat HIV have plummeted in recent years, The Associated Press reports. However, patents on newer therapies still keep those drugs’ prices heavily inflated by comparison, according to an annual report released by Médecins Sans Frontières/Doctors Without Borders (MSF) at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

The cost of the World Health Organization’s recommended single-pill triple-combination first-line ARV has dropped 19 percent in the last year, from $172 to $139 per person per year. Some countries are able to negotiate even lower prices by ordering large quantities.  Two second-line ARVs have each seen price drops of 28 percent in the past year, yielding a $303 price tag for the most affordable second-line therapy—a 75 percent reduction in overall cost since 2006.

Newer ARVs, however, are hugely expensive. The lowest price for a salvage regimen for those who have failed second-line treatment is $2,006 in the poorest nations, while countries that cannot access such cut rates pay much more. Thailand and Jamaica, for example, pay a respective $4,760 and $6,570 for the ARV Prezista (darunavir), while Paraguay must pay $7,782 for Intelence (etravirine) and Armenia’s price tag for Isentress (raltegravir) is $13,213.

“MSF and other care providers need the newer treatments for people that have exhausted all other options, but patents keep them priced beyond reach,” Jennifer Cohn, MD, medical director at MSF’s Access Campaign, said in a release. “We also need to watch carefully as newer, better medicines reach the market in coming years, as these are the drugs that we’ll quickly be needing to use. The price question is far from resolved.”

“Scaling up HIV treatment and sustaining people on treatment for life will depend on bringing the price of newer drugs down,” Arax Bozadjian, HIV pharmacist at MSF’s Access Campaign, said in a release. “Today, there are no quality-assured generic options for the large majority of the newer HIV drugs. Prices in middle-income countries are also a major concern. The terms of existing voluntary license agreements aren’t good enough; most of them don’t have terms that are public health–oriented; and most middle-income countries are excluded, which limits these countries’ access to much-needed regimens.”

To read the AP story, click here.

To read the Doctors Without Borders release, click here.

Search: HIV, generic drugs, antiretrovirals, Médecins Sans Frontières, Doctors Without Borders, MSF, 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, IAS 2013, Kuala Lumpur, World Health Organization, Prezista, darunavir, Intelence, etravirine, Isentress, raltegravir, Jennifer Cohn, Arax Bozadjian.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    soy_Ric
    Rochester
    New York


    usuallyhappy
    Palm Springs
    California


    kmfdm221
    Arcata
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.